Why Reactive Security Is Failing—And What Comes Next 
Monumental LLC Announces ‘Star Trek: Warp’ Collectible Card Game – Now Available to Wishlist on Steam Atreca Announces Oral Presentation of ATRC-101 Phase 1b Study Data at ASCO 2023 Annual Meeting
SAN CARLOS, Calif., April 26, 2023 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a…
Myriad Genetics to Release First Quarter Financial Results on May 3, 2023
SALT LAKE CITY, April 26, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a…
Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual Meeting
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage…
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
– Single Doses of ALN-APP Demonstrated Dose-Dependent, Rapid and Sustained Reduction of sAPPα and sAPPβ…
Allen Media Group to Leverage VideoAmp as New Currency for 2023-24 Upfront Season
The Weather Channel and VideoAmp Collaborate to Deliver Enhanced Metrics for Advertisers Through More Sophisticated…
eFFECTOR to Present Updated Clinical Data from Phase 2 Expansion Cohorts for Zotatifin in Patients with ER+ Metastatic Breast Cancer at ASCO 2023 Annual Meeting
eFFECTOR to host conference call following ASCO presentation SOLANA BEACH, Calif. and REDWOOD CITY, Calif.,…
NexImmune Announces Presentation of Phase 1/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting
GAITHERSBURG, Md., April 26, 2023 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company…
SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS)…
Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis
OLINGUITO Phase 3 program in adults with axial spondyloarthritis (AxSpA) to include two parallel studies…
Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer
CINCINNATI, April 26, 2023 (GLOBE NEWSWIRE) — Blue Water Biotech, Inc. (“Blue Water” or the…
Tiidal Receives Shareholder Approval for the Sale of Sportsflare and Announces Results of Its Meeting of Shareholders
Toronto, Ontario–(Newsfile Corp. – April 26, 2023) – Tiidal Gaming Group Corp. (CSE: TIDL) (the…
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Edgio, Inc. f/k/a Limelight Networks, Inc. (EGIO)
SAN DIEGO–(BUSINESS WIRE)–$EGIO #EdgioInc—The Class: Robbins LLP informs investors that a shareholder filed a class…
KDM Financial Approved as Third-Party SBA Lender
Company Now Serving Under Resourced Small, Medium Sized Business Often Turned Away by Traditional Banks…
Flinn Foundation Selects 20 Top Arizona Students for 2023 Flinn Scholarship
Flinn Scholars to receive full ride to a public Arizona university PHOENIX–(BUSINESS WIRE)–#ASU–Twenty Arizona high…
AirOps Announces $7M in Seed Funding to Bring GPT-4 Powered Tools to the Workplace
Built on OpenAI’s GPT-4 and other large language models, AirOps allows users to deploy AI…
Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”…
Ashvattha Therapeutics Presents Preclinical Data on anti-VEGF Nanomedicine D-4517.2 at the 2023 ARVO Annual Meeting
Data demonstrated that a single oral dose of D-4517.2 significantly reduced choroidal neovascularization (CNV) lesions…
Green Water Labs Introduces Algae Control, a Revolutionary Eco-Friendly Solution to Prevent and Eliminate Unwanted Algae Growth
SEATTLE, April 26, 2023 (GLOBE NEWSWIRE) — Green Water Labs, a leading manufacturer of eco-friendly…
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
European Commission Approval of Opfolda and Commercial Launch of Pombiliti®+ Opfolda®Anticipated in…
CHMP recommends EU approval of Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people…